A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 706
- 试验地点
- 273
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response [CR], very good partial response [VGPR], or partial response [PR]) to initial therapy and who have not undergone SCT.
详细描述
The drug being tested in this study is called ixazomib citrate. Ixazomib citrate is being tested to slow progressive disease (PD) and improve overall survival in people who have NDMM who have had a major positive response to initial therapy and have not undergone SCT. This study will look at the effect of ixazomib citrate has on the length of time that participants are free of PD and their overall survival.
The study will enrol approximately 700 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 3:2 ratio to Ixazomib or matching placebo groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
- Ixazomib citrate initiates at 3 mg which will be escalated to 4 mg with cycle 5 day 1
- Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient
All participants will be asked to take one capsule on Days 1, 8 and 15 of each 28-day cycle. The treatment period will be approximately 24 months (equivalent to 26 cycles) or until patients experience PD or unacceptable toxicities, whichever occurs first.
This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 78 to 106 months. Participants will make 28 visits to the clinic during the treatment period and will continue to make follow-up visits every 4 weeks until the next line of therapy begins. Participants will also be contacted by telephone every 12 weeks after last treatment visit for a follow-up assessment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult male or female participants 18 years or older with a confirmed diagnosis of symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria.
- •Completed 6 to 12 months (± 2 weeks) of initial therapy, during which the participant was treated to best response, defined as the best response maintained for 2 cycles after the M-protein nadir is reached.
- •Documented major response (PR, VGPR, CR) according to the International Myeloma Working Group (IMWG) uniform response criteria, version 2011, after this initial therapy.
- •Female participants who:
- •Are postmenopausal for at least 1 year before the screening visit, OR
- •Are surgically sterile, OR
- •If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, OR
- •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
- •Male participants, even if surgically sterilized (that is, status postvasectomy), who:
- •Agree to practice effective barrier contraception during the entire study Treatment period and through 90 days after the last dose of study drug, OR
- •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)
- •Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
- •Complete documentation of the details of the initial therapy before randomization including cytogenetics and International Staging System (ISS) is available.
- •Eastern Cooperative Oncology Group Performance Status of 0 to
- •Suitable venous access for the study-required blood sampling and consent for the specific amounts that will be taken.
- •Is willing and able to adhere to the study visit schedule and other protocol requirements including blood sampling and bone marrow aspiration.
- •Must meet the following clinical laboratory criteria at study entry:
- •Absolute neutrophil count (ANC) greater than or equal to (≥) 1,000 per cubic millimeter (/mm^3) without growth factor support and platelet count ≥75,000/mm^
- •Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before randomization.
- •Total bilirubin less than or equal to (≤) 1.5*the upper limit of the normal range (ULN).
- •Alanine aminotransferase and aspartate aminotransferase ≤ 3*ULN.
- •Calculated creatinine clearance ≥ 30 milliliter per minute (mL/min) (using the Cockcroft-Gault equation).
排除标准
- •Multiple myeloma that has relapsed after, or was not responsive to, initial therapy.
- •Radiotherapy within 14 days before randomization.
- •Diagnosed or treated for another malignancy within 5 years before randomization or previous diagnosis with another malignancy. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
- •Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.
- •Major surgery within 14 days before randomization.
- •Central nervous system involvement.
- •Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization.
- •Diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS), plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome.
- •Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
- •Systemic treatment with strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or St. John's wort within 14 days before randomization.
- •Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection.
- •Comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (example, PN that is Grade 1 with pain or Grade 2 or higher of any cause).
- •Psychiatric illness or social situation that would limit compliance with study requirements.
- •Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
- •Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
- •Treatment with any investigational products within 30 days before randomization.
研究组 & 干预措施
Placebo
Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.
干预措施: Placebo (Drug)
Ixazomib
Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.
干预措施: Ixazomib (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: From randomization until PD or death (up to 52 months)
PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an independent review committee (IRC) according to International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first. Per IMWG criteria, PD is defined as, increase of 25% of lowest response value in one or more of following criteria: serum M-component (absolute increase ≥0.5 g/ deciliter (dL)); or urine M-component (absolute increase ≥200 mg/24-hour); difference between involved and uninvolved free light chains (FLC) levels (absolute increase \>10 mg/dL); or bone marrow plasma cell percentage (absolute plasma cell percentage ≥10%); development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma; or development of hypercalcemia (corrected serum calcium \>11.5mg/dL).
次要结局
- Progression Free Survival 2 (PFS2)(From the date of randomization to every 12 weeks until second PD or death (up to 88 months))
- Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period(Up to 27 months)
- Time to Next Line Therapy (TTNT)(From randomization until PD or death (up to 52 months))
- Duration of Next-line Therapy(From randomization until PD or death (up to 52 months))
- Percentage of Participants Who Develop a New Primary Malignancy(From randomization until PD or death (up to 52 months))
- Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS)(Baseline, Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 (cycle length=28 days))
- Time to Progression (TTP)(From randomization until PD or death (up to 52 months))
- Time to Improvement of PN Events(Up to 52 months)
- PFS in a High-risk Population(From randomization until PD or death (up to 52 months))
- Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status(Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26, progression free survival follow-up (PFSFU)- Visit 37 and progressive disease follow-up (PDFU)- Visit 26 (cycle length=28 days))
- Correlation Between Frailty Status and PFS and OS(From randomization up to 52 months)
- Overall Survival (OS)(From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months))
- Time to End of the Next-line of Therapy After Study Treatment(From randomization until PD or death (up to 52 months))
- Correlation of MRD Status With PFS and OS(From randomization up to 52 months)
- OS in a High-risk Population(From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months))
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(First dose of study drug through 30 days after last dose of study drug (up to 88 months))
- Percentage of Participants With Conversion From Minimal Residual Disease (MRD) Positive to MRD Negative(Up to 52 months)
- Pharmacokinetic Parameter: Plasma Concentration of Ixazomib(Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days))
- Time to Resolution of Peripheral Neuropathy (PN) Events(Up to 52 months)